Moderna (MRNA) shares face significant pressure following the U.S. Food and Drug Administration's (FDA) refusal to review the company's application for its experimental mRNA-1010 flu vaccine. The regulatory agency issued a 'refusal to review' letter, citing fundamental concerns regarding the study's design and a lack of adequate, well-controlled data. This setback is compounded by a strategic pivot from the Department of Health and Human Services (HHS), which announced plans to wind down mRNA vaccine development and terminate related contracts. The HHS shift indicates a broader policy move away from mRNA platforms in favor of alternative vaccine technologies for respiratory infections. Analysts view this development as a major blow to Moderna’s pipeline, potentially threatening its long-term revenue growth and market valuation. The news has also triggered broader concerns across the biotechnology sector, impacting other mRNA-focused firms like BioNTech and Pfizer.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis